ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years
Chantale Bernatchez
Matched on ORCID iD 0000-0001-5926-3460; OpenAlex author ID A5051328429. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 37
2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper
Papers 5
- Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarci… Co-author DOI 10.1136/jitc-2023-006822↗
- Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. Last author DOI 10.1158/2159-8290.cd-21-1248↗
- Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies. Co-author DOI 10.1158/1078-0432.ccr-20-3925↗
- Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Co-author DOI 10.1073/pnas.1811067116↗
- 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-17-0831↗
Closest collaborators
The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Anirban Maitra · 4 shared papers, 2017–2022 · strength 0.35
- Paper Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-21-1248↗
- Paper Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-w… DOI 10.1158/1078-0432.ccr-20-3925↗
- Paper Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic… DOI 10.1073/pnas.1811067116↗
- Milind M. Javle · 3 shared papers, 2017–2024 · strength 0.33
- Paper Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal … DOI 10.1136/jitc-2023-006822↗
- Paper Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-21-1248↗
- Paper 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in … DOI 10.1158/1078-0432.ccr-17-0831↗
- Donastas Sakellariou-Thompson · 3 shared papers, 2017–2024 · strength 0.33
- Paper Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal … DOI 10.1136/jitc-2023-006822↗
- Paper Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-21-1248↗
- Paper 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in … DOI 10.1158/1078-0432.ccr-17-0831↗
- Michael James Overman · 3 shared papers, 2017–2024 · strength 0.28
- Paper Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal … DOI 10.1136/jitc-2023-006822↗
- Paper Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic… DOI 10.1073/pnas.1811067116↗
- Paper 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in … DOI 10.1158/1078-0432.ccr-17-0831↗
- Shubham Pant · 2 shared papers, 2022–2024 · strength 0.28
- Paper Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal … DOI 10.1136/jitc-2023-006822↗
- Paper Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-21-1248↗
- Ching-Wei David Tzeng · 2 shared papers, 2022–2024 · strength 0.28
- Paper Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal … DOI 10.1136/jitc-2023-006822↗
- Paper Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. DOI 10.1158/2159-8290.cd-21-1248↗
- Patrick Hwu · 2 shared papers, 2017–2024 · strength 0.21
- Paper Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal … DOI 10.1136/jitc-2023-006822↗
- Paper 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in … DOI 10.1158/1078-0432.ccr-17-0831↗
- Matthew H. G. Katz · 2 shared papers, 2019–2022 · strength 0.19
- Rodabe Navroze Amaria · 1 shared paper, 2024 · strength 0.16
- Robert A. Wolff · 1 shared paper, 2024 · strength 0.16
- Amir Anthony Jazaeri · 1 shared paper, 2024 · strength 0.16
- Scott Kopetz · 1 shared paper, 2024 · strength 0.16
- Ying Yuan · 1 shared paper, 2024 · strength 0.16
- Vincent Bernard · 2 shared papers, 2017–2021 · strength 0.16
- Paper Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-w… DOI 10.1158/1078-0432.ccr-20-3925↗
- Paper 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in … DOI 10.1158/1078-0432.ccr-17-0831↗
- Aislyn P. Schalck · 1 shared paper, 2022 · strength 0.12
- Michael P. Kim · 1 shared paper, 2022 · strength 0.12
- Alexander Semaan · 1 shared paper, 2021 · strength 0.11
- Maria E. Monberg · 1 shared paper, 2021 · strength 0.11
- Jaewon James Lee · 1 shared paper, 2021 · strength 0.11
- Paola A. Guerrero · 1 shared paper, 2021 · strength 0.11
- Cullen M. Taniguchi · 1 shared paper, 2021 · strength 0.11
- Daniel Lin · 1 shared paper, 2021 · strength 0.11
- Manoop S. Bhutani · 1 shared paper, 2021 · strength 0.11
- Brian R. Weston · 1 shared paper, 2021 · strength 0.11
- Huamin Wang · 1 shared paper, 2019 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.